Navigation Links
CEL-SCI Study Shows CEL-2000 Vaccine Blocks Progression of Rheumatoid Arthritis
Date:2/22/2010

reatments comprise an approximately $13 billion market.  Enbrel, a leading rheumatoid arthritis treatment sold by Amgen and Wyeth, reported US sales in 2007 of about $3.2 billion.  Enbrel is a soluble recombinant protein of a human TNF-alpha receptor linked to human IgG Fc.  In some cases, human or humanized monoclonal antibodies specific against TNF-alpha have also been used for therapy in rheumatoid arthritis.  These therapies remove or inactivate TNF-alpha, a natural human cytokine required in many immune functions for normal defenses.  

CEL-SCI's rheumatoid arthritis vaccine CEL-2000 was discovered as part of work with the Company's ongoing research and development activities with its L.E.A.P.S.™ (Ligand Epitope Antigen Presentation System) technology.  L.E.A.P.S. is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize proprietary immunogens. Any disease for which an antigenic sequence has been identified, such as infectious, parasitic, malignant or autoimmune diseases and allergies, are potential therapeutic or preventive sites for the application of L.E.A.P.S. technology.

The concept behind the L.E.A.P.S. technology is to directly mimic cell-cell interactions and activate immune cells with synthetic peptides. The L.E.A.P.S. constructs containing the antigenic disease epitope linked to a immune-cell binding ligand (ICBL) can be manufactured by peptide synthesis or by covalently linking the two peptides. Depending
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. CEL-SCI Corporation Releases Letter to Shareholders
2. CEL-SCI Corporation Reports First Quarter 2010 Financial Results
3. CEL-SCI to Present at 12th Annual BIO CEO & Investor Conference
4. CEL-SCI Hires Vice President of Manufacturing/Facilities and Commercial Operations
5. CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine
6. CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine
7. CEL-SCI Corporation Releases Letter to Shareholders
8. CEL-SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1-Infected Patients
9. CEL-SCI Expands H1N1 Flu Virus Work
10. CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
11. CEL-SCI Posts New Corporate Presentation to Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... RnRMarketResearch.com adds Corneal Ulcers ... to its store. This report p provides an ... The report "Corneal Ulcers - Pipeline Review, H2 2014" ... Corneal Ulcers. Corneal Ulcers are primarily result of ... infections & fungal infections. The symptoms of the ...
(Date:2/26/2015)... 26, 2015  AbbVie (NYSE: ABBV ... in its neuroscience and oncology development programs have ... American Academy of Neurology annual meeting in ... 18-25. The accepted abstracts feature results from studies ... investigational treatments in AbbVie,s pipeline. Presentations will include ...
(Date:2/26/2015)... , Feb. 26, 2015  IRIDEX Corporation (NASDAQ: ... quarter and full year 2014 financial results after the market ... with the release, the Company will host a conference call ... on Thursday, March 5, 2015 to discuss ... Interested parties may access the live conference call via ...
Breaking Medicine Technology:Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2
... 23, 2012 Idenix Pharmaceuticals, Inc. (NASDAQ: ... and development of drugs for the treatment of human ... fourth quarter and year ended December 31, 2011 as ... (HCV) development pipeline. Operational HighlightsIDX184 ...
... Psychemedics Corporation (NASDAQ: PMD ) today announced ... December 31, 2011.  The Company also announced an increase in ... of record as of March 5, 2012 to be paid ... consecutive quarterly dividend. The Company,s revenue for the ...
Cached Medicine Technology:Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 3Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 5Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 6Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 7Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 8Psychemedics Corporation Announces a 20% Increase in Revenue and a 34% Increase in Profits for 2011 Year End 2Psychemedics Corporation Announces a 20% Increase in Revenue and a 34% Increase in Profits for 2011 Year End 3Psychemedics Corporation Announces a 20% Increase in Revenue and a 34% Increase in Profits for 2011 Year End 4Psychemedics Corporation Announces a 20% Increase in Revenue and a 34% Increase in Profits for 2011 Year End 5
(Date:2/27/2015)... Altec Products, Inc., announced today that ... Document Management Partner of the Year. ADSS Global provides ... other complimentary solutions for their customers across the world. ... years to provide clients with paperless solutions that integrate ... are thrilled to recognize ADSS Global for their expertise ...
(Date:2/27/2015)... NY (PRWEB) February 27, 2015 In ... to the community by providing free dental care from ... has partnered with Dentistry from the Heart, and ... 11, 2015. The first 50 patients who are in ... they can’t afford, will have access to high­quality service ...
(Date:2/27/2015)... 2015 The federal court overseeing more ... use of the statin medication can increase a person’s ... new order pertaining discovery in the cases selected for ... comments. The Order, which was issued in the U.S. ... directs the parties to schedule certain witness depositions before ...
(Date:2/27/2015)... 2015 According to court documents, Donna ... June 25, 2013 and underwent a procedure during which ... mouth. Because the duodenoscope allegedly had not been ... “superbug” carbapenem-resistant Enterobacteriaceae (CRE). , A lawsuit ... County on behalf of Ms. Pirolli alleging that Lutheran ...
(Date:2/27/2015)... Beach, FL (PRWEB) February 27, 2015 ... medical companies, devices and pharmaceuticals, Benedict Advertising & ... as its newest client. The company’s patented NITROUSEAL® ... a pain-free, no-stress method of sedation. , Sedation ... medical patient comfort to a new level, though ...
Breaking Medicine News(10 mins):Health News:Altec Announces 2014 Sage ERP Document Management Partner of the Year Award Recipient 2Health News:Dr. Umanoff Unites with Dentistry from the Heart to Provide Community with Charitable Dental Care 2Health News:Dr. Umanoff Unites with Dentistry from the Heart to Provide Community with Charitable Dental Care 3Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 2Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 3Health News:Lawsuit Alleges Blame on Scope Manufacturer for "Superbug" Outbreak 2Health News:Benedict Advertising & Marketing Signs Sedation Systems 2
... ... Continuous Process Improvement (CPI) Training and Certification industry. They are making doing the right ... ... and Consulting Inc., a leader in Continuous Process Improvement (CPI) Training and Certification, ...
... 15 issue of the Journal of Clinical Sleep Medicine ... quality significantly increase the risk of motor vehicle accidents in ... likely to have had a crash if they experienced sleepiness ... bad sleep (OR = 1.9). Eighty of the 339 ...
... Watching TV medical shows might not be the best way ... Researchers screened the most popular medical dramas and found that ... almost half the time, according to a study released today ... 62nd Annual Meeting in Toronto April 10 to April 17, ...
... lead to new therapeutic targets for patients with the ... California, San Diego School of Medicine has identified a ... the study, published in the journal Nature Medicine ... protein called the peroxisome proliferator-activated receptor-γ (PPAR-γ) accounts for ...
... ... Made While Being Interviewed on the Joy Behar Show in January of 2010, Michelle ... of the Television Show "The Biggest Loser" and its Bombastic, Outspoken Trainer , ... (PRWEB) February 14, 2010 ...
... ... where organic style comes naturally, has just added the Aventura Organic ... of stylish organic clothes for men, women and children. The Aventura ... one garment at a time” mission and ‘hip’ fashions, is just ...
Cached Medicine News:Health News:Mountain Home 'Doing the Right Thing Really is the Best Business Approach' 2Health News:Mountain Home 'Doing the Right Thing Really is the Best Business Approach' 3Health News:Mountain Home 'Doing the Right Thing Really is the Best Business Approach' 4Health News:Sleep problems and sleepiness increase the risk of motor vehicle accidents in adolescents 2Health News:Defective signaling pathway sheds light on cystic fibrosis 2Health News:AntiBiggestLoser.com; New Blog Takes Aim at Worldwide Reality TV Show, "The Biggest Loser" 2Health News:AntiBiggestLoser.com; New Blog Takes Aim at Worldwide Reality TV Show, "The Biggest Loser" 3Health News:EdenHome.com Adds Aventura Organic Clothes to Site and Announces Largest Online Selection of Stylish Organic Clothes for Men, Women and Children 2Health News:EdenHome.com Adds Aventura Organic Clothes to Site and Announces Largest Online Selection of Stylish Organic Clothes for Men, Women and Children 3
... The CMGS-1 Color Mini-Ganzfeld Stimulator is ... can be integrated with your existing LKC ... with other visual electrodiagnostic test systems. ... is the smallest commercial Ganzfeld to meet ...
... the most advanced visual electrodiagnostic system ... of retinal and optic nerve function. ... drives this powerful computer-controlled instrument. With ... pattern stimulation, rapid Ganzfeld flash rate ...
... designed to facilitate an arthrodesis, either by ... interbody cages allowing radicular compression by restoring ... and of the foramina, which in turn ... for major lumbar instabilities.,CC cages are made ...
... SHELLGEL is a sterile nonpyrogenic, transparent ... SHELLGEL contains 12 mg/mL of high molecular ... hyaluronate dissolved in physiological saline. In the ... is 105,000 cps (105 Pa s) at ...
Medicine Products: